PRNB

SC 13G/A - Principia Biopharma Inc. (0001510487) (Subject)

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc., a Sanofi company, focused on developing treatments for immune mediated diseases, today announced it has completed patient enrollment into the global Phase 3 PEGASUS trial for rilzabrutinib, an oral investigational Bruton tyrosine kinase (BTK) inhibitor.  “We are pleased with the speed of recruitment and would like to thank investigators and study coordinators, and most importantly the patients who are volunteering to be part of a potential groundbreaking clinical trial,” said Dolca Thomas, MD, chief medical officer at Principia.  “Since there continues to be a significant need for treatment options am

-NL-201 IND submission anticipated by year end 2020- -Clinical Trial Notification application submitted in Australia- -Ended 3rd quarter with $201.2 million in cash and cash equivalents- SEATTLE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third quarter ended September 30, 2020. “The past quarter has been highly productive at Neoleukin as we continue to advance NL-201 toward an IND and prepare to initiate our first clinical trial in patients with a

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune mediated diseases, today announced that the first patient was dosed in an open label two-arm trial to evaluate rilzabrutinib in IgG4-related disease (RD).  “IgG4-RD is a serious fibro-inflammatory disease that can affect nearly any organ. The disease has long been under-diagnosed and under-treated, so we believe there is a significant medical need to have fast acting steroid free treatments with persistent responses. We believe rilzabrutinib has the potential to lead to positive outcomes in IgG4-RD by

SAN DIEGO, Sept. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY).   On August 17, 2020, Principia announced that it had entered into a definitive merger agreement with Sanofi. Under the terms of the acquisition agreement, the Company's shareholders will receive $100 per share in cash.  The investigation concerns whether the Principia board failed to satisfy its duties to the Company shareholders, including whether the board